TY - JOUR
T1 - Quality of Life in Myeloproliferative Neoplasms
T2 - Symptoms and Management Implications
AU - Mesa, Ruben
AU - Palmer, Jeanne
AU - Eckert, Ryan
AU - Huberty, Jennifer
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/4
Y1 - 2021/4
N2 - Myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, and myelofibrosis. They are characterized by abnormal myeloid proliferation. Patients suffer from debilitating constitutional symptoms and splenomegaly. There have been advances in understanding the impact on quality of life in myeloproliferative neoplasms. Owing to the chronicity of these diseases, symptoms are considered in response criteria for clinical trials. This review wills cover how quality of life is measured in patients with myeloproliferative neoplasm. We review the impact of treatment options, including JAK inhibitors, allogeneic stem cell transplantation, and medications in development. We discuss nonpharmacologic methods of improving symptoms and quality of life.
AB - Myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, and myelofibrosis. They are characterized by abnormal myeloid proliferation. Patients suffer from debilitating constitutional symptoms and splenomegaly. There have been advances in understanding the impact on quality of life in myeloproliferative neoplasms. Owing to the chronicity of these diseases, symptoms are considered in response criteria for clinical trials. This review wills cover how quality of life is measured in patients with myeloproliferative neoplasm. We review the impact of treatment options, including JAK inhibitors, allogeneic stem cell transplantation, and medications in development. We discuss nonpharmacologic methods of improving symptoms and quality of life.
KW - Inflammation
KW - Integrative medicine
KW - Myeloproliferative neoplasm
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85099858580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099858580&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2020.12.006
DO - 10.1016/j.hoc.2020.12.006
M3 - Review article
C2 - 33641875
AN - SCOPUS:85099858580
SN - 0889-8588
VL - 35
SP - 375
EP - 390
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 2
ER -